• Karyopharm scheduled a June 2, 2026 investor call to discuss Phase 3 SENTRY results for selinexor with ruxolitinib in myelofibrosis.
• The data were presented at the 2026 ASCO Annual Meeting in an oral session led by principal investigator John Mascarenhas.
• The update highlights the combination’s clinical performance in myelofibrosis, informing the program’s next regulatory and commercial steps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.